Literature DB >> 27257196

Draft Genome Sequence of Oral Bacterium Streptococcus mutans JH1140.

Jerome Escano1, Peng Deng2, Shi-En Lu2, Lief Smith3.   

Abstract

Streptococcus mutans JH1140 is an oral bacterium known to produce the bacteriocin mutacin 1140, and the strain has been genetically engineered to combat dental caries. Here, we report the 2.0-Mb draft genome of S. mutans JH1140. This genome provides new insights into the strain's superior colonization properties and its utility in replacement therapy.
Copyright © 2016 Escano et al.

Entities:  

Year:  2016        PMID: 27257196      PMCID: PMC4891642          DOI: 10.1128/genomeA.00472-16

Source DB:  PubMed          Journal:  Genome Announc


GENOME ANNOUNCEMENT

Dental caries is considered one of the most widespread chronic diseases afflicting the global population (1). Due to its production of lactic acid, the oral bacterium Streptococcus mutans is considered to be one of the major causes of dental caries (2). S. mutans JH1140 has been genetically modified to prevent dental caries (3). The technology is referred to as “replacement therapy” and stems from engineering the JH1140 strain to produce less acid. Gram-positive lactic acid bacteria, such as S. mutans, are known to produce bacteriocins (4). The ability of JH1140 to produce a potent bacteriocin enables the engineered replacement therapy strain BCS3-L1 to colonize the oral cavity of those inoculated. Mutacin 1140 is a bacteriocin produced by S. mutans JH1140. It belongs to a class of peptide antibiotics called lantibiotics (5). Mutacin 1140 has been shown to have a broad spectrum of activity against Gram-positive pathogens. Many bacteria are known to contain genes for more than one bacteriocin. Yet, many of these genes are expressed only under certain conditions, undermining efforts to isolate these bacteriocins. Assembly of the S. mutans JH1140 genome has helped identify novel bacteriocins and provided further understanding of the effector strain BCS3-L1’s superior colonization properties that facilitated its development as a replacement therapy strain. S. mutans JH1140 was found to contain a single lactate dehydrogenase gene, which was predicted, given that this gene was mutated in the replacement therapy strain BCS3-L1. Aside from the mutacin 1140 operon, S. mutans JH1140 was found to contain two additional lantibiotic gene clusters. The first cluster contains similar genes for the two-component lantibiotic Smb (6). The other cluster contains three genes that encode a lantibiotic similar to nukacin (7). The nukacin-like gene cluster is the first instance of a lantibiotic gene cluster containing three repetitive genes that encode a similar lantibiotic. It is interesting to note that the Smb and nukacin-like lantibiotics have never been isolated from S. mutans JH1140. Strain JH1140 was provided by the American Type Culture Collection (ATCC 55676). Genomic DNA from S. mutans JH1140 was isolated using an adapted protocol (8). Whole-genome sequencing was performed using the Illumina MiSeq 2 × 250-bp paired-end sequencer (Illumina, San Diego, CA) at the Genome Sequencing and Analysis Facility (University of Texas, Austin, TX). A total of 3,476,154 short reads (1 Gb) were de novo assembled using the ABySS version 1.9.0 and DNAstar SeqMan NGen version 12 softwares. The assembled genome had 525× genome coverage. The draft S. mutans JH1140 genome contains 24 contigs and has an approximate size of 2 Mb, with a G+C content of 36.6%. Gene annotation was performed by the NCBI Prokaryotic Genome Annotation Pipeline using the GeneMarkS+ version 3.1 software. The genome annotation consisted of 1,901 protein-coding genes, with 379 of them being hypothetical protein-coding genes. There were 61 RNA genes predicted in the genome annotation, consisting of genes encoding 50 tRNAs and 7 rRNAs.

Nucleotide sequence accession number.

This draft genome sequence has been deposited at GenBank under the accession no. LTAK00000000.
  8 in total

Review 1.  Dental caries.

Authors:  Robert H Selwitz; Amid I Ismail; Nigel B Pitts
Journal:  Lancet       Date:  2007-01-06       Impact factor: 79.321

Review 2.  Role of Streptococcus mutans in human dental decay.

Authors:  W J Loesche
Journal:  Microbiol Rev       Date:  1986-12

3.  Genetic analysis of a unique bacteriocin, Smb, produced by Streptococcus mutans GS5.

Authors:  Hideo Yonezawa; Howard K Kuramitsu
Journal:  Antimicrob Agents Chemother       Date:  2005-02       Impact factor: 5.191

4.  Site-directed mutations in the lanthipeptide mutacin 1140.

Authors:  Shaorong Chen; Shawanda Wilson-Stanford; William Cromwell; Jeffrey D Hillman; Adam Guerrero; Charlotte A Allen; Joseph A Sorg; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2013-04-19       Impact factor: 4.792

5.  Nukacin ISK-1, a bacteriostatic lantibiotic.

Authors:  Sikder M Asaduzzaman; Jun-ichi Nagao; Hiroshi Iida; Takeshi Zendo; Jiro Nakayama; Kenji Sonomoto
Journal:  Antimicrob Agents Chemother       Date:  2009-06-08       Impact factor: 5.191

Review 6.  Genetically modified Streptococcus mutans for the prevention of dental caries.

Authors:  Jeffrey D Hillman
Journal:  Antonie Van Leeuwenhoek       Date:  2002-08       Impact factor: 2.271

Review 7.  Bacteriocins of lactic acid bacteria: extending the family.

Authors:  Patricia Alvarez-Sieiro; Manuel Montalbán-López; Dongdong Mu; Oscar P Kuipers
Journal:  Appl Microbiol Biotechnol       Date:  2016-02-10       Impact factor: 4.813

8.  Bile acid recognition by the Clostridium difficile germinant receptor, CspC, is important for establishing infection.

Authors:  Michael B Francis; Charlotte A Allen; Ritu Shrestha; Joseph A Sorg
Journal:  PLoS Pathog       Date:  2013-05-09       Impact factor: 6.823

  8 in total
  3 in total

1.  Modifying the Lantibiotic Mutacin 1140 for Increased Yield, Activity, and Stability.

Authors:  Mengxin Geng; Leif Smith
Journal:  Appl Environ Microbiol       Date:  2018-07-17       Impact factor: 4.792

2.  Mutacin 1140 Lantibiotic Variants Are Efficacious Against Clostridium difficile Infection.

Authors:  Johan A Kers; Robert E Sharp; Anthony W Defusco; Jae H Park; Jin Xu; Mark E Pulse; William J Weiss; Martin Handfield
Journal:  Front Microbiol       Date:  2018-03-16       Impact factor: 5.640

3.  OG716: Designing a fit-for-purpose lantibiotic for the treatment of Clostridium difficile infections.

Authors:  Johan A Kers; Anthony W DeFusco; Jae H Park; Jin Xu; Mark E Pulse; William J Weiss; Martin Handfield
Journal:  PLoS One       Date:  2018-06-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.